Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly

Shares of Novo Nordisk tumbled Monday after the company announced its experimental weight-loss drug, CagriSema, did not meet its primary goal in a clinical trial. The stock fell as much as 13% following the disclosure, hitting its lowest level since July 2021.

Novo Nordisk’s Setback and the Competitive Landscape

CagriSema, intended as a next-generation treatment for obesity, failed to demonstrate it was not inferior to tirzepatide, a drug developed by Eli Lilly. After 84 weeks, patients taking a 2.4 mg dose of CagriSema experienced 23% weight loss, compared to 25.5% weight loss among those taking a 15 mg dose of tirzepatide. Tirzepatide is the active ingredient in Eli Lilly’s Mounjaro and Zepbound, which have recently surpassed Novo Nordisk’s Ozempic and Wegovy in U.S. Prescriptions.

Did You Know? Novo Nordisk predicts its sales and profit growth could decline by between 5% and 13% in 2026, citing increased competition and pricing pressures.

The disappointing trial results represent a setback for Novo Nordisk as it seeks to maintain its dominance in the rapidly growing weight-loss market. The company is continuing to explore additional trials for CagriSema, including testing higher doses, and remains optimistic about its potential. According to Chief Scientific Officer Martin Holst Lange, CagriSema “has the potential to be the first GLP-1/amylin-combination product to reach the market.”

Market Reaction

The market reacted swiftly to the news. Novo Nordisk’s Copenhagen-listed shares closed down 12.9% at 263 Danish kroner. Conversely, Eli Lilly’s stock rose 3.5% in premarket trading. This shift reflects investor confidence in Lilly’s existing weight-loss drugs and potential concerns about Novo Nordisk’s future performance.

Expert Insight: The failure of CagriSema to demonstrate non-inferiority to tirzepatide underscores the intensifying competition in the weight-loss pharmaceutical sector. Companies are now facing increased pressure to not only develop effective treatments but also to prove their superiority or, at minimum, equivalence to existing market leaders.

Novo Nordisk CEO Mike Doustdar acknowledged the challenges ahead, stating, “People should expect that it goes down before it comes back up.” This statement suggests the company anticipates a period of adjustment as it navigates these competitive pressures.

Frequently Asked Questions

What is CagriSema?

CagriSema is Novo Nordisk’s experimental weight-loss drug that combines semaglutide and cagrilintide, a hormone affecting appetite.

What is tirzepatide?

Tirzepatide is the active ingredient in Eli Lilly’s weight-loss drugs Mounjaro and Zepbound.

What did Novo Nordisk’s CEO say about the company’s future?

Novo Nordisk CEO Mike Doustdar told CNBC that investors should anticipate a decline before a potential recovery in the company’s performance.

How will Novo Nordisk adapt to increased competition in the weight-loss drug market?